MELD

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Retrieved on: 
Monday, April 1, 2024
MELD, Metabolism, Regeneration, Dicarboxylic acid, Survival, Liver disease, PD, Safety, Patient, History, Alkaline phosphatase, CYP1A2, Crosstalk (biology), ASGR1, Pharmacokinetics, Therapy, ALP, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.   The Phase 1a study was completed in February 2024. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.   The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.

Key Points: 
  • SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.
  • The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.
  • The randomized, placebo-controlled Phase 1a trial enrolled a total of 48 subjects, including 40 healthy volunteers and 8 patients with cirrhosis and a history of liver disease.
  • Cirrhotic patients also showed evidence of liver function effects after treatment with SZN-043 as measured by HepQuant which is a test that measures cholate clearance, a liver specific function that quantifies liver function.

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Alcoholism, Atopic dermatitis, Cholesterol, Metabolism, Multimedia, IND, Alcoholic hepatitis, Disease, Mortality, AMD, Body surface area, Therapy, MELD, Clinical trial, Hospital, Telecanthus, DSM-IV codes, Spasticity, Protocol, Cirrhosis, Biomarker, Triglyceride, Syndrome, Ethanol, Patient, Safety, RASP, Retina, Pharmaceutical industry

ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.

Key Points: 
  • ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.
  • Highlighting the advancement of the RASP platform and the selection of key clinical indications for future development, Aldeyra released a focused pipeline.
  • “With the success achieved in our ADX-629 program, which includes a number of positive, signal-finding clinical results, we are excited to advance our RASP modulator pipeline to systemic and retinal immune-mediated diseases, as well as metabolic diseases, exacerbated by RASP,” stated Dr. Brady.
  • “We anticipate 2024 to provide a variety of clinical-stage catalysts, as Aldeyra continues to progress its novel RASP platform.”

AMRA Medical at AASLD The Liver Meeting® Showcases MRI-Based Technology and Muscle Biomarkers linked to liver disease severity and progression

Retrieved on: 
Thursday, November 9, 2023
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, MELD, DSM-IV codes, Biomarker, Cirrhosis, Liver, Prevalence, Non-alcoholic fatty liver disease, Frailty, Liver disease, Phenotype, Multimedia, CVD, Circulatory system, Bilirubin, Mass, Type 2 diabetes, Cardiovascular disease, Abstract, AASLD, NAFLD, Patient, Sarcopenia, Medical imaging, Dietary supplement, T2D

A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.

Key Points: 
  • A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.
  • View the full release here: https://www.businesswire.com/news/home/20231109684555/en/
    The abstracts present MAsS as a promising tool to identify physical frailty and sarcopenia and as prognostic biomarkers for liver disease.
  • The AASLD’s The Liver Meeting® takes place November 10-14th in Boston, USA, with a number of AMRA attendees.
  • Those joining us at The Liver Meeting® can learn about how the MAsS biomarkers, muscle fat infiltration and muscle volume z-score, have been utilized in studies from early to end-stage liver disease.

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 15, 2023
Drug development, NASH, Hepatocellular carcinoma, Liver disease, GGT, COVID-19, Food and Drug Administration, Cancer, Cirrhosis, FVC, Cough, LOXL2, Model for End-Stage Liver Disease, Fibrosis, Vital capacity, Patient, Investment, Periodic breathing, ALT, Mortality, FDA, IPF, Death, AST, Idiopathic pulmonary fibrosis, Food, Safety, Pharmaceutical industry, Medical device, Medicine, MELD, Hepatology, Galecto Biotech

Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.

Key Points: 
  • Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.
  • “We are very disappointed that the GALACTIC-1 results do not support the continued development of GB0139 as a new treatment for IPF,” said Hans Schambye, President and Chief Executive Officer of Galecto.
  • The trial compared treatment with the inhaled 3 mg dose of GB0139 to placebo (randomized 2:1) over 52 weeks.
  • Galecto previously announced topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, its orally available galectin-3 inhibitor, for the treatment of decompensated cirrhosis.

The Universal Peace Gala: A Benefit in Support of the Universal Peace Sanctuary in Lumbini, Nepal

Retrieved on: 
Wednesday, May 10, 2023
Crypto, Tether, Bitcoin, EOS, Blockchain Capital, NFT, MELD, Mother, Nowness, Investment, Beverly Wilshire Hotel, Eminence, Face, Business, Digital twin, Growth, IDEO, Multiplier, EOS.IO, Blockchain, Animoca Brands, CUDOS, History, Government, Web 2.0, Volkswagen, Love, Tata Consultancy Services, Bitcoin Foundation, LOS, Partnership, Habit, Thomson Reuters, BT, Wave Financial, Non-fungible token, City, Skype, United Arab Emirates, Nightclub, Arms industry, Cryptocurrency, Convent

LOS ANGELES, May 9, 2023 /PRNewswire-PRWeb/ -- The gala is a benefit in support of the Universal Peace Sanctuary, now under construction in Lumbini, Nepal. The theme is "Make Peace More Fashionable Than War". The sanctuary will serve as a radiant beacon, guiding individuals, communities and nations toward peace, non-violence and reconciliation.

Key Points: 
  • LOS ANGELES, May 9, 2023 /PRNewswire-PRWeb/ -- The gala is a benefit in support of the Universal Peace Sanctuary, now under construction in Lumbini, Nepal.
  • His Eminence Shyalpa Tenzin Rinpoche is the visionary founder of the Universal Peace Sanctuary.
  • Launch of the Universal Peace Movement The gala will also serve as the launch of the Universal Peace Movement, an initiative aimed at raising funds for the construction of the Universal Peace Sanctuary and its Digital Twin.
  • The Universal Peace Sanctuary is a non-profit project that promotes peace, compassion, and understanding among all people and all nations.

Global AI Training Dataset Market Report 2023: Rapid Development of AI and Learning Machines Drives Demand

Retrieved on: 
Thursday, March 16, 2023
Acquisition, NLP, Machine learning, Artificial intelligence, Classification, Crowdsourcing, Waymo, Microsoft, Mining, Pedestrian, Lidar, BFSI, MELD, OpenAI, Figure Eight Inc., Algorithm, Government, Personal data, Health, Amazon, Knowledge, Growth, Data, EHR, Big data, Marketing, ChatGPT, Electronic health record, Data set, Intelligence, ML, AI, Video game, Mobile phone, Medical device

The global market for AI training datasets is projected to expand at a CAGR of 22.5% during the forecast period 2023 and 2031.

Key Points: 
  • The global market for AI training datasets is projected to expand at a CAGR of 22.5% during the forecast period 2023 and 2031.
  • In addition to creating opportunities for new entrants, the rising demand for application-specific training data is generating new business opportunities.
  • Innovation and technological advancement in AI are accelerating the expansion of the market for AI training datasets.
  • Asia-Pacific is the largest contributor to the global market for AI training datasets and is projected to expand at a CAGR of 21.5% over the forecast period.

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Retrieved on: 
Tuesday, November 8, 2022
Private Securities Litigation Reform Act, Fibrosis, Idiopathic pulmonary fibrosis, Cirrhosis, Galecto Biotech, Securities and Exchange Commission (Philippines), PK, Fatty liver disease, Ruxolitinib, LOXL2, Hepatitis, Institute of Liver and Biliary Sciences, Large-cell lung carcinoma, Liver, Liver failure, SEC, Patient, Safety, Pharmacokinetics, Cancer, MELD, IPF, NSCLC, Security (finance), Alcoholic liver disease, Pharmaceutical industry

Cirrhosis primarily caused by non-alcoholic steatohepatitis, alcoholic liver disease and hepatitis is the end stage of progressive liver fibrosis and the leading cause of liver-related death globally.

Key Points: 
  • Cirrhosis primarily caused by non-alcoholic steatohepatitis, alcoholic liver disease and hepatitis is the end stage of progressive liver fibrosis and the leading cause of liver-related death globally.
  • This study includes patients with decompensated cirrhosis (Child-Pugh Classes B and C).
  • Patients are randomized 1:1 to receive oral GB1211 100mg or placebo twice daily for 12 weeks.
  • Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Retrieved on: 
Sunday, November 6, 2022
Komodo, Therapy, EC, Primary biliary cholangitis, SMR, GLOBE, PBC, FDA, Death, Safety, Liver support system, Nasdaq, AASLD, Originality, Fatty liver disease, OCA, MELD, Obeticholic acid, Association, Patient, Pharmaceutical industry, Dietary supplement, Medical imaging

MORRISTOWN, N.J., Nov. 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced that results from two analyses assessing the potential of obeticholic acid (OCA) to improve outcomes for patients with primary biliary cholangitis (PBC), including death, liver transplant and hepatic decompensation, will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • COBALT was a randomized, double-blind, placebo-controlled confirmatory trial designed to assess efficacy and safety of OCA in patients with advanced PBC.
  • The study looked at a pre-defined group of patients with PBC who were treated with OCA and a comparable group of PBC patients who were eligible, but who were not treated with OCA.
  • Characteristics of patients who initiated treatment with OCA were SMR-weighted to OCA-eligible patients not treated with OCA.
  • This press release contains forward-looking statements (FLS), including regarding the results of our clinical studies, and the safety and efficacy of OCA.

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Retrieved on: 
Wednesday, August 31, 2022
Mortality, Hepatic encephalopathy, NASDAQ, Model for End-Stage Liver Disease, Incidence, Ascites, GLOBE, Therapy, NASH, Fatty liver disease, MELD, Patient, Pharmaceutical industry, Dietary supplement, Medical imaging

MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.

Key Points: 
  • MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, The MAESTRO-NASH Outcomes study is designed to address an urgent unmet need for patients and expand the long-term commercial opportunity for resmetirom.
  • Positive results from this study could support full approval in the noncirrhotic population and potential for approval in an additional indication in patients with well-compensated NASH cirrhosis.
  • In addition, this study has the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis.

New York City-based MELD Advertising Opens Office in Dubai

Retrieved on: 
Thursday, August 4, 2022
CEO, Weight Watchers, Technology, GCC, Silver Tower, Advertising, MELD, Farmers Insurance Group, Tourism, Cigna, Jumeirah Lakes Towers Free Zone, Operations Director, Silver Towers, Insurance, Ethics, Health, MetLife, Management

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- MELD Advertising has opened a new office in Dubai, United Arab Emirates.

Key Points: 
  • NEW YORK, Aug. 4, 2022 /PRNewswire/ -- MELD Advertising has opened a new office in Dubai, United Arab Emirates.
  • After building a client list that includes Cigna, Farmers Insurance, MetLife, and Weight Watchers, MELD Advertising, based in New York City, has expanded to the Middle East, opening an office at the Silver Tower in the DMCC Free Zone.
  • Derek Wood, CEO and Executive Creative Director, said, "Choosing Dubai to open our second office was easy.
  • MELD Advertising was built on a foundation that focuses on humanity, transparency, and strong ethics.